Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Benitec Biopharma

- PMLiVE

NHS England launches pilot programme for high street pharmacy referrals

The scheme aims to diagnose more early stage cancers without the need for a GP appointment

- PMLiVE

UK government allocates up to £680m a year to two funds offering cutting-edge treatments

The new Innovative Medicines Fund will enable patients in England to gain fast-track access to drug treatments

- PMLiVE

bluebird bio maintains its focus on gene therapy opportunities during structural changes

The company plans to reduce its workforce amid efforts to reduce its operating costs

- PMLiVE

Novartis and Voyager Therapeutics agree on gene therapy deal worth 1.7bn

The licence option agreement is for next-generation gene therapy vectors for neurological diseases

- PMLiVE

bluebird bio shares therapy updates for 2022

The company provided information for its first two gene therapies and its lovo-cel BLA submission for sickle cell disease

Takeda agrees on $2bn deal with Code Bio to expand its gene therapy programmes

The pharma company will gain opt-in rights for four rare diseases candidates

Biomarin

FDA keeps BioMarin’s gene therapy for phenylketonuria on hold

The decision follows data suggesting BioMarin’s experimental gene therapies may have the potential to progress cancers

- PMLiVE

Six million patients affected by delay to NHS England’s plans to address COVID-19 backlog

UK’s health and social care secretary Sajid Javid said that the number of patients on these hospital waiting lists would increase before beginning to fall

- PMLiVE

New drug available on NHS will benefit lung cancer patients

Over 850 patients in England diagnosed with NSCLC will be able to access the treatment in year one, with numbers tipped to rise to more than 1,000 patients in year...

- PMLiVE

bluebird bio’s beti-cel accepted for priority review by FDA

The tough journey to approval for beta-thalassemia gene therapy (beti-cel) in the US may be coming to an end, with approval possible by 2022

Disrupting Cell Engineering with Non-Viral Modalities

Jessica Schwaber, Scientific Director, Cell & Gene Therapy, Avectas, explores her company’s unique cell engineering platform, the recent shift in cell & gene therapy commercial needs, current barriers to realizing...

Impetus Digital

- PMLiVE

AbbVie signs gene therapy deal in eye care

AbbVie and REGENXBIO have teamed up on RGX-314, a potential one-time gene therapy against two leading causes of blindness, wet AMD and diabetic retinopathy.

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links